This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Number of primary studies included
13 studies were included in the review.
Methods of combining primary studies
Not reported.
Investigation of differences between primary studies
Results of the review
The results of the review were as follows (Ranges tested in the sensitivity analysis are shown in parentheses): Hepatitis virus complications: acute symptomatic hepatitis after HCV transmission = 40% (range 25% -100%); after HBV transmission = 100%; fulminant hepatitis if acute hepatitis (80% mortality) = 0.2%; chronic hepatitis after acute HBV 5% (range: 1% -25%); symptoms if chronic HBV infection = 15% (range: 1% -50%); interferon treatment if chronic hepatitis = 50% (range: 10% -100%).
Quality adjustments for health states varied from 0.25 (range: 0.1 -0.7) for AIDS to 1 without complications.
Relative risk of mortality: AIDS (males and females) = x20; decompensated cirrhosis (males) = x3.14 (range: x1.04 -x9.42); and (females) x2.84 (range: x1.00 -x8.52).
These data formed the principal inputs to the model.
Methods used to derive estimates of effectiveness
Authors estimates, based on data in the literature.
Estimates of effectiveness and key assumptions
It was assumed that 5% of patients infected with HBV would develop chronic hepatitis after 6-months, and that it
